Items Tagged ‘News’

May 18th, 2017

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer

By

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or C.  These study results were […]

View full entry

Tags: CheckMate 040 nivolumab, immuno-oncology, Liver Cancer, News, opdivo, PD-1, Precision Cancer Medicine


May 17th, 2017

Skin Cancer Prevention Tips from the Skin Cancer Foundation

By

The development of skin cancer is certainly a risk for any individual, but particularly for those of us who spend time in the outdoors. As summer approaches it’s important to keep in mind that by taking certain steps to protect yourself from the sun, you can safely enjoy your time outside. The following recommendations from […]

View full entry

Tags: Health and Wellness, News, Skin Cancer, Skin cancer health and wellness


May 16th, 2017

Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks

By

More than half of breast cancer patients (57 percent) undergoing mastectomy lack the necessary medical knowledge to make a high-quality decision about reconstructive surgery that aligns with their personal goals, suggesting a trend toward overtreatment, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer […]

View full entry

Tags: Breast Cancer, mastectomy, News, Reconstructive Surgery


May 15th, 2017

Avelumab Immunotherapy Approved for Bladder Cancer

By

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- CancerConnect. About Urothelial Cancer Bladder […]

View full entry

Tags: Bavencio Avelumab, Bladder Cancer, News, precison medicine


May 11th, 2017

FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 precision cancer medicine, in combination with Alimta®  (pemetrexed) and carboplatin chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for […]

View full entry

Tags: keytruda, Lung Cancer, News, nsclc, PD-1, precision cancer immunotherapy


May 11th, 2017

FDA Approves Imfinzi for Treatment of Urothelial Cancer

By

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type […]

View full entry

Tags: Bladder Cancer, durvalumab, Imfinzi, immunotherapy, News, PD-1, urothelial carcinoma


May 8th, 2017

First New Drug for Liver Cancer in a Decade: Stivarga

By

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a decade. Stivarga is an oral […]

View full entry

Tags: immunotherapy, Liver Cancer, News, regorafenib, Stivarga


May 4th, 2017

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

By

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions (CR). About axicabtagene ciloleucel Axicabtagene […]

View full entry

Tags: CAR T, HD, HNL, immunotherapy, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


May 3rd, 2017

Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms

By

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis are asymptomatic and only in more severe cases are these patients subjected to minimally invasive […]

View full entry

Tags: cancer risk, endometriosis, News, ovarian, Ovarian Cancer


May 2nd, 2017

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th!

By

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions about chronic myeloid leukemia (CML) on CancerConnect. CancerConnect is an online support community for individuals affected by cancer. Dr. Luskin […]

View full entry

Tags: Chronic Myeloid Leukemia, cml expert, expert, Leukemia, News


May 1st, 2017

Check It Out: May is Skin Cancer Awareness Month

By

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which accounts for approximately 1% of cases. In 2016, the ACS estimates 76,380 […]

View full entry

Tags: awareness, General Skin Cancer, infographic, Melanoma, News, Recurrent Melanoma, Screening/Prevention Melanoma, Skin Cancer, Stage III Melanoma, Stage IV Melanoma, Stages I-II Melanoma, support


April 26th, 2017

SWOG Study Shows Strong Long-Term Survival Rates for Patients with GIST

By

PORTLAND, OR – Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed as Gleevec. SWOG researchers are back with long-term findings from that study, which estimate that nearly one in four patients treated with […]

View full entry

Tags: clinical trial archive gist, Gastrointestinal Stromal Tumors, Gist, News


April 25th, 2017

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

By

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal, Blood raises concerns about the safety of Revlimd maintenance reporting an increased risk of developing secondary cancer. Doctors from the Institute of Cancer Research […]

View full entry

Tags: maintenance therapy, Multiple Myeloma, News, revlimid


April 25th, 2017

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial

By

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it to destroy ovarian cancer cells […]

View full entry

Tags: clinical trial, immunotherpay, News, Ovarian Cancer, precision medicine, vaccine


April 24th, 2017

Immune Therapy Produces Anti-Cancer Responses in Advanced Cervical Cancer

By

Adoptive T-cell therapy (ACT) appears to provide anti-cancer responses among patients with advanced cervical cancer for whom standard therapy has stopped working. These results were published in the Journal of Clinical Oncology. The most common cause of cervical cancer is infection with particular strains of the human papillomavirus (HPV). As such, vaccinations against the virus […]

View full entry

Tags: adoptive T cell therapy, Cervical Cancer, cervical cancer immune therapy, News